Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists
摘要:
Preclinical studies suggest that compounds with dual norepinephrine reuptake inhibitor (NRI) and 5-HT1A partial agonist properties may provide an important new therapeutic approach to ADHD, depression, and anxiety. Reported herein is the discovery of a novel chemical series with a favorable NRI and 5-HT1A partial agonist pharmacological pro. le as well as excellent selectivity for the norepinephrine transporter over the dopamine transporter. (C) 2009 Elsevier Ltd. All rights reserved.
Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists
摘要:
Preclinical studies suggest that compounds with dual norepinephrine reuptake inhibitor (NRI) and 5-HT1A partial agonist properties may provide an important new therapeutic approach to ADHD, depression, and anxiety. Reported herein is the discovery of a novel chemical series with a favorable NRI and 5-HT1A partial agonist pharmacological pro. le as well as excellent selectivity for the norepinephrine transporter over the dopamine transporter. (C) 2009 Elsevier Ltd. All rights reserved.
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists
作者:Amy B. Dounay、Nancy S. Barta、Brian M. Campbell、Corey Coleman、Elizabeth M. Collantes、Lynne Denny、Satavisha Dutta、David L. Gray、Dongfeng Hou、Rathna Iyer、Samarendra N. Maiti、Daniel F. Ortwine、Al Probert、Nancy C. Stratman、Rajendra Subedi、Tammy Whisman、Wenjian Xu、Kim Zoski
DOI:10.1016/j.bmcl.2009.12.023
日期:2010.2
Preclinical studies suggest that compounds with dual norepinephrine reuptake inhibitor (NRI) and 5-HT1A partial agonist properties may provide an important new therapeutic approach to ADHD, depression, and anxiety. Reported herein is the discovery of a novel chemical series with a favorable NRI and 5-HT1A partial agonist pharmacological pro. le as well as excellent selectivity for the norepinephrine transporter over the dopamine transporter. (C) 2009 Elsevier Ltd. All rights reserved.